12:00 AM
Aug 06, 2012
 |  BC Week In Review  |  Company News  |  Other News

Intellipharmaceutics, AstraZeneca neurology, drug delivery news

AstraZeneca granted Intellipharmaceutics rights to market generic versions of the 50, 150, 200, 300 and 400 mg strengths of AstraZeneca's antipsychotic Seroquel XR quetiapine fumarate in the U.S. on Nov. 1, 2016, or earlier...

Read the full 160 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >